Author

Mihaela Mureşan

Observed names: M M Muresan, M. Muresan, MIHAELA MURESAN, Mihaela Muresan

Observed institutions: Inserm, Institut Pasteur, Universidade Estadual de Campinas (UNICAMP), Bon Secours Hospital Cork, Instituto de Salud Carlos III, Différenciation et Communication Neuronale et Neuroendocrine, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Régional et Universitaire de Nancy, Centre for Biomedical Network Research on Rare Diseases, Université Paris Descartes, Université Henri Poincaré, University College London, Université de Rouen Normandie

OpenAlex ID: A5073851014

Mutations in NR5A1 Associated with Ovarian Insufficiency

2009 · Diana Lourenço, Raja Brauner, et al. · New England Journal of Medicine · 405

Bone metastases from differentiated thyroid carcinoma

2008 · M M Muresan, P Olivier, et al. · Endocrine Related Cancer · 261

Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

2009 · Hartmut P.H. Neumann, Zoran Erlic, et al. · Cancer Research · 193

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10

2010 · Karin Frank-Raue, Lisa A. Rybicki, et al. · Human Mutation · 149

Dominant-Negative GCMB Mutations Cause an Autosomal Dominant Form of Hypoparathyroidism

2008 · Michael Mannstadt, Guylène Bertrand, et al. · The Journal of Clinical Endocrinology & Metabolism · 103

Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma Malignancy

2007 · Erwan Thouënnon, Abdel G. Elkahloun, et al. · The Journal of Clinical Endocrinology & Metabolism · 67

Systematic comparison of sporadic and syndromic pancreatic islet cell tumors

2010 · Zoran Erlic, Ursula Ploeckinger, et al. · Endocrine Related Cancer · 45

Mutations in NR5A1 Associated With Ovarian Insufficiency

2009 · Diana Lourenço, Raja Brauner, et al. · Obstetrical & Gynecological Survey · 34

Circulating EM66 is a highly sensitive marker for the diagnosis and follow‐up of pheochromocytoma

2005 · Johann Guillemot, Youssef Anouar, et al. · International Journal of Cancer · 30

Development of Novel Tools for the Diagnosis and Prognosis of Pheochromocytoma Using Peptide Marker Immunoassay and Gene Expression Profiling Approaches

2006 · YOUSSEF ANOUAR, LAURENT YON, et al. · Annals of the New York Academy of Sciences · 24

Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival

2010 · Erwan Thouënnon, Alice Pierre, et al. · Endocrine Related Cancer · 22

Expression and Processing of the Neuroendocrine Protein Secretogranin II in Benign and Malignant Pheochromocytomas

2006 · JOHANN GUILLEMOT, LAURE BARBIER, et al. · Annals of the New York Academy of Sciences · 21

Recombinant Human Thyrotropin Stimulates Thyroid Angiogenesis In Vivo

2006 · Marc Klein, Laurent Brunaud, et al. · Thyroid · 20

Characterization and Plasma Measurement of the WE-14 Peptide in Patients with Pheochromocytoma

2014 · Johann Guillemot, Marlène Guérin, et al. · PLoS ONE · 18

Data from Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

2023 · Hartmut P.H. Neumann, Zoran Erlic, et al.

Supplementary Table 1 Legends and References from Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

2023 · Hartmut P.H. Neumann, Zoran Erlic, et al.

Supplementary Table 1 from Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

2023 · Hartmut P.H. Neumann, Zoran Erlic, et al.

Other Supporting Colleagues from Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

2023 · Hartmut P.H. Neumann, Zoran Erlic, et al.

Supplementary Table 2 from Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

2023 · Hartmut P.H. Neumann, Zoran Erlic, et al.

Supplementary Table 2 from Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out

2023 · Hartmut P.H. Neumann, Zoran Erlic, et al.

P77. Guided bone regeneration for bisphosphonate-induced osteonecrosis of the jaws

2008 · Pierre Mouret, Hervé Moizan, et al. · Cancer Treatment Reviews

P1-090 - Hypoparathyroïdie par mutation activatrice du récepteur calcique : à propos d’un cas

2006 · M. Muresan, L. Trabelsi, et al. · Annales d Endocrinologie

Identification of two granin-derived peptides as diagnostic markers of pheochromocytomas

2006 · Y. Anouar, J. Guillemot, et al. · Frontiers in Neuroendocrinology

P088 - Identification d’une nouvelle forme de macrodélétion du gène SDHB dans un cas de paragangliome familial

2005 · L. Trabelsi, M. Muresan, et al. · Annales d Endocrinologie

P225 - Phéochromocytome-paragangliome familial avec une nouvelle mutation sdh : débat sur la bénignité/malignité et la mutation sdhd

2004 · M. Muresan, E. Mongeois, et al. · Annales d Endocrinologie

Works count: 25

Citation count: 1,392

H-index: 14

I10-index: 14